{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:35:02Z","timestamp":1789079702471,"version":"build-2803163510"},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T00:00:00Z","timestamp":1514332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Alemtuzumab as part of the conditioning protocol is effective in reducing graft\u2010versus\u2010host disease (Gv<jats:styled-content style=\"fixed-case\">HD<\/jats:styled-content>), but may be associated with increased infection rates, especially when using high doses (ie, 100\u00a0mg).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective, single\u2010center, case\u2010control study analyzing the rates of neutropenic fever, cytomegalovirus (<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>) reactivation, Epstein\u2010Barr virus (<jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content>) reactivation, clinical manifest toxoplasmosis, and clinical manifest human herpesvirus\u20106 (<jats:styled-content style=\"fixed-case\">HHV<\/jats:styled-content>6) infection using low\u2010dose alemtuzumab in comparison with anti\u2010thymocyte globulin (<jats:styled-content style=\"fixed-case\">ATG<\/jats:styled-content>) as Gv<jats:styled-content style=\"fixed-case\">HD<\/jats:styled-content> prophylaxis before allogeneic stem cell transplantation. Forty\u2010four patients transplanted from unrelated donors between 2001 and 2012 were matched by age, diagnosis, and conditioning regimen and treated either with alemtuzumab 10\u00a0mg at day \u22122 (respectively, 20\u00a0mg in case of mismatch transplantation) or <jats:styled-content style=\"fixed-case\">ATG<\/jats:styled-content>. <jats:styled-content style=\"fixed-case\">ATG<\/jats:styled-content> Fresenius (10\u00a0mg\/kg for 3\u00a0days) or Thymoglobulin (2\u00a0mg\/kg for 3\u00a0days) were used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Rates of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> reactivation, <jats:styled-content style=\"fixed-case\">EBV<\/jats:styled-content> reactivation, and clinical manifest <jats:styled-content style=\"fixed-case\">HHV<\/jats:styled-content>6 infection or toxoplasmosis did not differ significantly between both groups until 2\u00a0years after transplantation. No case of post\u2010transplant lymphoproliferative disorder was observed. Also, rates of neutropenic fever during inpatient treatment after transplantation did not differ significantly in both groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We saw no indication of increased infections rates when using low\u2010dose alemtuzumab as Gv<jats:styled-content style=\"fixed-case\">HD<\/jats:styled-content> prophylaxis before allogeneic stem cell transplantation in this retrospective analysis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12822","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T11:33:04Z","timestamp":1511782384000},"source":"Crossref","is-referenced-by-count":8,"title":["No indication of increased infection rates using low\u2010dose alemtuzumab instead of anti\u2010thymocyte globulin as graft\u2010versus\u2010host disease prophylaxis before allogeneic stem cell transplantation"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1160-1277","authenticated-orcid":false,"given":"Thomas","family":"Neumann","sequence":"first","affiliation":[{"name":"Department of Haematology, Oncology, Transplantation University Medical Centre Ernst\u2010Moritz\u2010Arndt University  Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Schneidewind","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oncology, Transplantation University Medical Centre Ernst\u2010Moritz\u2010Arndt University  Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Thiele","sequence":"additional","affiliation":[{"name":"Institute of Immunology and Transfusion Medicine University Medical Centre Ernst\u2010Moritz\u2010Arndt University  Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pink","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oncology HELIOS Klinikum Bad Saarow  Bad Saarow Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Schulze","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Wolgast Hospital  Wolgast Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oncology, Transplantation University Medical Centre Ernst\u2010Moritz\u2010Arndt University  Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kr\u00fcger","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oncology, Transplantation University Medical Centre Ernst\u2010Moritz\u2010Arndt University  Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12,27]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"213","article-title":"Anti\u2010human thymocyte globulin (ATG) for prophylaxis and treatment of graft\u2010versus\u2010host disease in recipients of allogeneic marrow grafts","volume":"10","author":"Weiden PL","year":"1978","journal-title":"Transplant Proc"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198202183060703"},{"key":"e_1_2_8_4_1","first-page":"CD009159","article-title":"Polyclonal anti\u2010thymocyte globulins for the prophylaxis of graft\u2010versus\u2010host disease after allogeneic stem cell or bone marrow transplantation in adults","volume":"9","author":"Theurich S","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70225-6"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2005.1702"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1182\/blood.V92.12.4581","article-title":"Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft\u2010versus\u2010host disease and graft rejection","volume":"92","author":"Hale G","year":"1998","journal-title":"Blood"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.7.2419"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2011.592824"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0701"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.09.001"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06759.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.01.021"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705911"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705263"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2003.11.001"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4357"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705164"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2009.00414.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05513.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-332007"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-286856"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.08.002"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1714-4"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2114-7"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1340"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.272"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.02.010"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.07.006"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.05.023"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.273"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2010.00504.x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705121"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212465215"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702503"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01724.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2004.00075.x"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2003.09.006"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12822","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:56:32Z","timestamp":1695473792000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,27]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/tid.12822"],"URL":"https:\/\/doi.org\/10.1111\/tid.12822","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,27]]},"article-number":"e12822"}}